1
|
Thompson LD: Osteosarcoma. Ear Nose Throat
J. 92:288–290. 2013.PubMed/NCBI
|
2
|
PosthumaDeBoer J, Witlox MA, Kaspers GJ
and van Royen BJ: Molecular alterations as target for therapy in
metastatic osteosarcoma: A review of literature. Clin Exp
Metastasis. 28:493–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Yang J and Zhang W: New molecular insights
into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406.
2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Namløs HM, Meza-Zepeda LA, Barøy T,
Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H,
Cleton-Jansen AM and Myklebost O: Modulation of the osteosarcoma
expression phenotype by microRNAs. PLoS One. 7:e480862012.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Braccini L, Ciraolo E, Martini M, Pirali
T, Germena G, Rolfo K and Hirsch E: PI3K keeps the balance between
metabolism and cancer. Adv Biol Regul. 52:389–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wu P and Hu YZ: PI3K/Akt/mTOR pathway
inhibitors in cancer: A perspective on clinical progress. Curr Med
Chem. 17:4326–4341. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Perry JA, Kiezun A, Tonzi P, Van Allen EM,
Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS,
et al: Complementary genomic approaches highlight the PI3K/mTOR
pathway as a common vulnerability in osteosarcoma. Proc Natl Acad
Sci USA. 111:E5564–E5573. 2014. View Article : Google Scholar : PubMed/NCBI
|
9
|
Yang L, Shu T, Liang Y, Gu W, Wang C, Song
X, Fan C and Wang W: GDC-0152 attenuates the malignant progression
of osteosarcoma promoted by ANGPTL2 via PI3K/AKT but not p38MAPK
signaling pathway. Int J Oncol. 46:1651–1658. 2015.PubMed/NCBI
|
10
|
Eng C: PTEN: One gene, many syndromes. Hum
Mutat. 22:183–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
11
|
Hodakoski C, Hopkins BD, Barrows D, Mense
SM, Keniry M, Anderson KE, Kern PA, Hawkins PT, Stephens LR and
Parsons R: Regulation of PTEN inhibition by the pleckstrin homology
domain of P-REX2 during insulin signaling and glucose homeostasis.
Proc Natl Acad Sci USA. 111:155–160. 2014. View Article : Google Scholar :
|
12
|
Donald S, Hill K, Lecureuil C, Barnouin R,
Krugmann S, John Coadwell W, Andrews SR, Walker SA, Hawkins PT,
Stephens LR and Welch HC: P-Rex2, a new guanine-nucleotide exchange
factor for Rac. FEBS Lett. 572:172–176. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Fine B, Hodakoski C, Koujak S, Su T, Saal
LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S, et al:
Activation of the PI3K pathway in cancer through inhibition of PTEN
by exchange factor P-REX2a. Science. 325:1261–1265. 2009.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Guo B, Liu L, Yao J, Ma R, Chang D, Li Z,
Song T and Huang C: miR-338-3p suppresses gastric cancer
progression through a PTEN-AKT axis by targeting P-REX2a. Mol
Cancer Res. 12:313–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
15
|
Chen X, Pan M, Han L, Lu H, Hao X and Dong
Q: miR-338-3p suppresses neuroblastoma proliferation, invasion and
migration through targeting PREX2a. FEBS Lett. 587:3729–3737. 2013.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Berger MF, Hodis E, Heffernan TP, Deribe
YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E,
Ghosh P, et al: Melanoma genome sequencing reveals frequent PREX2
mutations. Nature. 485:502–506. 2012.PubMed/NCBI
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
18
|
Rosenfeldt H, Vázquez-Prado J and Gutkind
JS: P-REX2, a novel PI-3-kinase sensitive Rac exchange factor. FEBS
Lett. 572:167–171. 2004. View Article : Google Scholar : PubMed/NCBI
|
19
|
Leslie NR: P-REX2a driving tumorigenesis
by PTEN inhibition. Sci Signal. 2:pe682009. View Article : Google Scholar : PubMed/NCBI
|
20
|
Qin J, Xie Y, Wang B, Hoshino M, Wolff DW,
Zhao J, Scofield MA, Dowd FJ, Lin MF and Tu Y: Upregulation of
PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer
metastasis. Oncogene. 28:1853–1863. 2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Montero JC, Seoane S, Ocaña A and
Pandiella A: P-Rex1 participates in Neuregulin-ErbB signal
transduction and its expression correlates with patient outcome in
breast cancer. Oncogene. 30:1059–1071. 2011. View Article : Google Scholar
|
22
|
Donald S, Humby T, Fyfe I, Segonds-Pichon
A, Walker SA, Andrews SR, Coadwell WJ, Emson P, Wilkinson LS and
Welch HC: P-Rex2 regulates Purkinje cell dendrite morphology and
motor coordination. Proc Natl Acad Sci USA. 105:4483–4488. 2008.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Pandiella A and Montero JC: Molecular
pathways: P-Rex in cancer. Clin Cancer Res. 19:4564–4569. 2013.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Wang JY, Wu PK, Chen PC, Yen CC, Hung GY,
Chen CF, Hung SC, Tsai SF, Liu CL, Chen TH and Chen WM:
Manipulation therapy prior to diagnosis induced primary
osteosarcoma metastasis - from clinical to basic research. PLoS
One. 9:e965712014. View Article : Google Scholar
|
25
|
Fromigué O, Hamidouche Z and Marie PJ:
Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces
osteosarcoma cell invasion. J Biol Chem. 283:30549–30556. 2008.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Chueh FS, Chen YY, Huang AC, Ho HC, Liao
CL, Yang JS, Kuo CL and Chung JG: Bufalin-inhibited migration and
invasion in human osteosarcoma U-2 OS cells is carried out by
suppression of the matrix metalloproteinase-2, ERK, and JNK
signaling pathways. Environ Toxicol. 29:21–29. 2014. View Article : Google Scholar
|
27
|
Jin J, Cai L, Liu ZM and Zhou XS:
miRNA-218 inhibits osteosarcoma cell migration and invasion by
down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev.
14:3681–3684. 2013. View Article : Google Scholar : PubMed/NCBI
|